News articles about Omnicell (NASDAQ:OMCL) have trended somewhat positive on Wednesday, Accern reports. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Omnicell earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave news headlines about the company an impact score of 46.6056107104602 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the headlines that may have impacted Accern Sentiment’s scoring:
- Analyzing Omnicell (OMCL) & The Competition (americanbankingnews.com)
- $0.41 EPS Expected for Omnicell, Inc. (OMCL) This Quarter (americanbankingnews.com)
- Glens Falls Hospital Selects Omnicell Medication Management Solutions to … (prnewswire.com)
- Omnicell Reaches Analyst Target Price (thestreet.com)
- Omnicell (OMCL) Retains Buy Ranking (investorplace.com)
Omnicell (OMCL) traded up 0.10% on Wednesday, reaching $51.70. 19,976 shares of the company traded hands. Omnicell has a 1-year low of $30.35 and a 1-year high of $52.70. The stock’s market capitalization is $1.94 billion. The stock’s 50-day moving average is $50.19 and its 200-day moving average is $44.94.
Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, July 27th. The company reported $0.02 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.02. Omnicell had a negative net margin of 1.14% and a positive return on equity of 0.41%. The business had revenue of $180.90 million during the quarter, compared to analysts’ expectations of $174.08 million. During the same period in the prior year, the company earned $0.38 earnings per share. The firm’s revenue was up 4.6% on a year-over-year basis. Equities research analysts expect that Omnicell will post $1.30 EPS for the current year.
Several equities research analysts have recently issued reports on OMCL shares. Dougherty & Co raised their price target on shares of Omnicell from $45.00 to $49.00 and gave the stock a “buy” rating in a research note on Friday, July 28th. Craig Hallum raised their price target on shares of Omnicell from $46.00 to $52.00 and gave the stock a “buy” rating in a research note on Friday, July 28th. Cantor Fitzgerald restated a “buy” rating and set a $47.00 price target on shares of Omnicell in a research note on Tuesday, July 25th. Benchmark Co. raised their price target on shares of Omnicell from $55.00 to $67.00 and gave the stock a “buy” rating in a research note on Tuesday, September 5th. Finally, BidaskClub lowered shares of Omnicell from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Omnicell has a consensus rating of “Buy” and an average target price of $51.57.
COPYRIGHT VIOLATION NOTICE: This piece was originally posted by Markets Daily and is the property of of Markets Daily. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this piece can be read at https://www.themarketsdaily.com/2017/10/11/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-omnicell-omcl-stock-price.html.
In other news, Director Gary S. Petersmeyer sold 1,000 shares of the stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $51.73, for a total value of $51,730.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Robin Gene Seim sold 15,109 shares of the stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $50.86, for a total transaction of $768,443.74. Following the completion of the sale, the executive vice president now directly owns 58,144 shares of the company’s stock, valued at $2,957,203.84. The disclosure for this sale can be found here. Over the last three months, insiders sold 184,094 shares of company stock valued at $9,094,791. Corporate insiders own 3.77% of the company’s stock.
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.